Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Bone Metastasis
100%
Chemotherapy
100%
Hormonal Therapy
100%
Breast Carcinoma
100%
Bone Lesions
50%
5-fluorouracil (5-FU)
50%
Cyclophosphamide
37%
Doxorubicin
25%
Complete Response
25%
Partial Response
25%
Systemic Chemotherapy
25%
Microenvironment
12%
Skeletal-related Events
12%
Growth Factors
12%
Objective Response
12%
Bisphosphonates
12%
Letrozole
12%
No Significant Difference
12%
High Incidence
12%
Response Rate
12%
New Combination
12%
Combination Chemotherapy
12%
Objective Response Rate
12%
Paclitaxel
12%
Methotrexate
12%
Hormone-dependent
12%
Metastasizing
12%
Duration of Response
12%
Disease Stabilization
12%
Metastatic Lesions
12%
Bone Pain
12%
Prolonged Survival
12%
Skeletal Morbidity
12%
Chemotherapy Regimen
12%
Clinical Course
12%
International Unions
12%
Aromatase Inhibitors
12%
Fadrozole
12%
Megestrol Acetate
12%
Specific Growth
12%
Hypercalcemia
12%
Patient Benefit
12%
Clonal Selection
12%
Clinical Complications
12%
Long-stay Patients
12%
Parathyroid Hormone-related Protein (PTHrP)
12%
Clinical Problems
12%
Proclivity
12%
Vinorelbine
12%
Aminoglutethimide
12%
Osteolytic Bone Lesions
12%
Mitoxantrone
12%
Neurologic Complications
12%
Supportive Therapy
12%
Two-agent
12%
Medroxyprogesterone Acetate
12%
High Response Rate
12%
Osseous Metastasis
12%
Pathologic Fracture
12%
Lytic Bone Metastasis
12%
Anastrozole
12%
MD Anderson Cancer Center
12%
Medicine and Dentistry
Bone Metastasis
100%
Hormone Therapy
100%
Breast Carcinoma
100%
Bone Lesion
55%
Cyclophosphamide
33%
Malignant Neoplasm
22%
Doxorubicin
22%
Fluorouracil
22%
Diseases
22%
Letrozole
11%
Aromatase Inhibitor
11%
Combination Chemotherapy
11%
Skeleton
11%
Growth Factor
11%
Cytokine
11%
Paclitaxel
11%
Methotrexate
11%
Tamoxifen
11%
Bone Pain
11%
Bisphosphonate
11%
Neurological Complication
11%
Disease Course
11%
Hypercalcaemia
11%
Pathologic Fracture
11%
Parathyroid Hormone-Related Protein
11%
Mitoxantrone
11%
Vinorelbine
11%
Fadrozole
11%
Aminoglutethimide
11%
Anastrozole
11%
Chemotherapy
11%
Depo-Provera
11%
Medroxyprogesterone Acetate
11%
Pharmacology, Toxicology and Pharmaceutical Science
Bone Metastasis
100%
Chemotherapy
100%
Hormone Cancer Therapy
100%
Breast Carcinoma
100%
Bone Lesion
45%
Cyclophosphamide
27%
Malignant Neoplasm
18%
Fluorouracil
18%
Doxorubicin
18%
Diseases
18%
Tamoxifen
9%
Growth Factor
9%
Bisphosphonic Acid Derivative
9%
Aromatase Inhibitor
9%
Paclitaxel
9%
Cytokine
9%
Bone Pain
9%
Disease Course
9%
Methotrexate
9%
Fadrozole
9%
Megestrol Acetate
9%
Hypercalcaemia
9%
Neurological Complication
9%
Parathyroid Hormone Related Protein
9%
Mitoxantrone
9%
Vinorelbine
9%
Aminoglutethimide
9%
Medroxyprogesterone Acetate
9%
Letrozole
9%
Anastrozole
9%
Pathologic Fracture
9%
Immunology and Microbiology
Megestrol Acetate
33%
Clonal Selection
33%